Q BioMed Inc. Updates on COVID-19 Therapeutic Development and Clinical Trials – MAN-19 therapeutic program heading to clinical trial in early 2022
New York, NY – September 22, 2021 – Q BioMed Inc. (OTCQB: QBIO) a commercial stage biotechnology acceleration company, is pleased to provide an update on its partner asset MAN-19 for the treatment of Acute Respiratory Distress Syndrome (ARDS), a condition caused by viral infections in the lungs including COVID-19. The MAN-19 therapeutic is […]
Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Notice of Allowance for Patent in South Korea and Shows Promising Results in Initial Pre-Clinical Testing
New York, NY – August 24, 2021 – Q BioMed Inc. (OTCQB: QBIO) a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical assets in the healthcare sector, asset Uttroside B – is expected to receive a patent in Korea, adding to the already issued patents in Canada and Japan. In […]
Q BIOMED TO SCALE UP PRODUCTION OF UTTROSIDE-B, A NOVEL CHEMOTHERAPEUTIC FOR LIVER CANCER, IN PREPARATION FOR IND FILING
Q BioMed continues its collaboration with Chemveda Life Sciences to prepare for pre-clinical evaluation, Orphan Drug filing and Investigational New Drug (IND) filing of Uttroside-B Novel Therapeutic Shows Remarkable Efficacy in HepG2 Cell Lines New York, NY – July 22, 2020 – Q BioMed, Inc. (OTCQB: QBIO) and Chemveda Life Sciences are very […]
Q BioMed Initiates Rapid Development of Novel COVID-19 Therapeutics
Artificial Intelligence (AI) and computational biophysics will be deployed to rapidly develop drugs for COVID-19 and other viral infections based on Mannin Research’s Tie2 platform in new joint venture with Cyclica NEW YORK, April 21, 2020 – Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, today announced that together with its technology […]
Q BioMed Enters into a Financial Restructuring of Approximately $7,800,000 Consisting of $4,000,000 New Cash and a minimum of $3,800,000 of Debt Conversion
Sets Roadmap to Uplisting and Provides Cash Runway to 2021 and Beyond New York, NY – April 7, 2020 – Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today the entering of a significant financial transaction with its lead investor, Yorkville Advisors Global (“YA”). Under the agreement, on closing, YA will […]
Q BioMed Treats its First Patient in Commercial Setting Following Product Launch
Full commercial launch expected in the coming weeks of March An estimated 10 million people are living worldwide with pain from bone metastases New York, NY – March 12, 2020 – Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today the first patient has been dosed in a commercial setting with […]
Q BioMed Launches Non-Opioid Treatment for Metastatic Bone Pain
First orders for product received, with initial doses to ship in February Full commercial production and availability starting in March New York, NY – February 13, 2020 – Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today the launch of its FDA approved non-opioid drug Strontium89 (Strontium Chloride Sr-89 Injection, USP), […]
Q BioMed Announces FDA Approval
Company Gets Green Light for Manufacturing FDA Approved Non-Opioid Cancer Palliation Drug New York, NY – November 20, 2019 – Q BioMed Inc. (OTCQB: QBIO) announces FDA approval of its contract manufacturer IsoTherapeutics Group LLC (ITG). ITG is now cleared to manufacture the Company’s FDA approved non-opioid cancer bone pain drug Strontium-89 Chloride USP. […]
In a Major Breakthrough Q BioMed Discovers First Biomarkers for Pediatric Nonverbal Autism Subgroup
Marks the first time a company has identified biomarkers that hold the potential to stratify this subset of patients Study examined 1,953 significant autistic biomarkers, resulting in 2 significant markers tied to expressed genes and pathways responsible for speech development Biomarkers in the nonverbal subset were distinct from children with typical speech development […]
Q BioMed Inc Announces Acquisition of Cancer Pain Drug Metastron™ from GE Healthcare
Strategic Acquisition Gives Company Ownership of Brand Name Drug and Related Market Authorizations in 22 Countries in Which Metastron™ is Already Registered and Approved for Sale NEW YORK, November 28, 2018 — Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company, is pleased to announce that it has entered into agreement to acquire the […]
